Prostate cancer: Prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression

Barboro,Paola; Salvi,Sandra; Rubagotti,Alessandra; Boccardo,Simona; Spina,Bruno; Truini,Mauro; Carmignani,Giorgio; Introini,Carlo; Ferrari,Nicoletta; Boccardo,Francesco; Balbi,Cecilia

doi:10.3892/ijo.2014.2345

Prostate cancer: Prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression

Authors:
- Paola Barboro
- Sandra Salvi
- Alessandra Rubagotti
- Simona Boccardo
- Bruno Spina
- Mauro Truini
- Giorgio Carmignani
- Carlo Introini
- Nicoletta Ferrari
- Francesco Boccardo
- Cecilia Balbi
View Affiliations

Affiliations: IRCCS San Martino University Hospital, IST National Cancer Research Institute, I-16132 Genova, Italy, Academic Department of Medical Oncology and IRCCS San Martino University Hospital, IST National Cancer Research Institute, I-16132 Genova, Italy, Academic Department of Surgical Sciences, School of Medicine and IRCCS San Martino University Hospital, IST National Cancer Research Institute, I-16132 Genova, Italy
Published online on: March 14, 2014 https://doi.org/10.3892/ijo.2014.2345
Pages: 1589-1598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The management of prostate cancer (PCa) remains challenging because to date, there has been no way to distinguish between indolent and aggressive tumors. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is implicated in the network of mechanisms that control androgen receptor (AR) expression. We studied the expression of the two proteins in PCa to evaluate their prognostic potential and elucidate the hnRNP K function in PCa progression. HnRNP K and AR expression were analyzed immunohistochemically in 105 patients who had undergone radical prostatectomy. The association between the expression of hnRNP K and/or AR and PSA progression or death was evaluated by univariate and multivariate analyses. The expression of hnRNP K was also investigated in vitro using the BPH-1 cell line and two different LNCaP populations that recapitulate the progression of PCa towards a more aggressive disease. AR and hnRNP K were differentially expressed between cancer and normal prostate tissues. A strong association with a good prognosis was evident in PCa exhibiting high percentage of AR-positive cells (>75%) (p≤0.005) and more interestingly, the combination of high AR and low cytoplasmic hnRNP K expression emerged as the most significant independent prognostic marker for PSA failure-free survival, in a multivariate analysis (p≤0.001). In vitro, a higher expression of hnRNP K and pERK was associated with higher PSA levels, suggesting a relationship between hnRNP K phosphorylation and AR-regulated genes. These results indicate that the interaction between the AR and hnRNP K has an important role in the progression of PCa. Changes of the expression of the two proteins are strongly associated with the clinical outcome and may be a potential prognostic marker.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2.	Stamey TA: Preoperative serum prostate-specific antigen (PSA) below 10 μg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem. 47:631–634. 2001.PubMed/NCBI
3.	Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR and Yarbro JW: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 124:995–1000. 2000.PubMed/NCBI
4.	Humphrey PA and Vollmer RT: Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol. 10:326–333. 1997.PubMed/NCBI
5.	Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, Pontes JE and Wood DP Jr: Should Gleason score 7 prostate cancer be considered a unique grade category? Urology. 53:372–377. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G and Algaba F: Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int. 95:1146–1152. 2005.
7.	Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D, Adam RM, Rubin MA, Raychaudhuri P, De Benedetti A and Freeman MR: Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res. 69:2210–2218. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B, Truini M, Introini C, Puppo P, Ferrari N, Carmignani G, Boccardo F and Balbi C: Heterogeneous nuclear ribonucleo-protein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer. 100:1608–1616. 2009. View Article : Google Scholar
9.	Bomsztyk K, Denisenko O and Ostrowski J: hnRNP K: one protein multiple processes. Bioessays. 26:629–638. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Ostrowski J and Bomsztyk K: Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer. 89:1493–1501. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT and Murray GI: The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 1765:85–100. 2006.PubMed/NCBI
12.	Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C and Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localized and is associated with poor prognosis in colorectal cancer. Br J Cancer. 95:921–927. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Chen LC, Hsueh C, Tsang NM, Liang Y, Chang KP, Hao SP, Yu JS and Chang YS: Heterogeneous nuclear ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res. 14:3807–3813. 2008. View Article : Google Scholar
14.	Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, Chauhan SS, Srivastava A, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R and Siu KWM: Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer. 125:1398–1406. 2009. View Article : Google Scholar
15.	Chen LC, Chung IC, Hsueh C, Tsang NM, Chi LM, Liang Y, Chen CC, Wang LJ and Chang YS: The antiapoptotic protein FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ. 17:1463–1473. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Wen F, Shen A, Shanas R, Bhattacharyya A, Lian F, Hostetter G and Shi J: Higher expression of the heterogeneous nuclear ribonucleoprotein K in melanoma. Ann Surg Oncol. 17:2619–2627. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Hope NR and Murray GI: The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Human Pathol. 42:392–402. 2011.
18.	Wang F, Zhang P, Shi C, Yang Y and Qin H: Immunohisto-chemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol. 29:1780–1788. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R and Naaby-Hansen S: Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene. 23:1693–1703. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, Melamed J, Liu XM, Kurek R, Ossowski L and Ferrari AC: Androgen receptor overexpression in prostate cancer linked to Purα loss from a novel repressor complex. Cancer Res. 68:2678–2688. 2008.
21.	Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolò G, Barboro P, Parodi S, Patrone E and Balbi C: Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate. 55:259–264. 2003. View Article : Google Scholar
22.	Ricci F, Rubagotti A, Zinoli L, Mangerini R, Nuzzo PV, Carmignani G, Simonato A, Barboro P, Balbi C and Boccardo F: Prognostic value of nuclear matrix protein expression in localized prostate cancer. J Cancer Res Clin Oncol. 138:1379–1384. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F and Balbi C: Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate. 71:1466–1479. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Igawa T, Lin FF, Lee MS, Karan D, Batra SK and Lin MF: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate. 50:222–235. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG and Kung HJ: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 62:6606–6614. 2002.PubMed/NCBI
26.	Barboro P, Rubagotti A, Orecchia P, Spina B, Truini M, Repaci E, Carmignani G, Romagnoli A, Introini C, Boccardo F, Carnemolla B and Balbi C: Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol. 30:13–26. 2008.
27.	Kim D, Gregory CW, Smith GJ and Mohler JL: Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry. 35:2–10. 1999. View Article : Google Scholar : PubMed/NCBI
28.	Fleiss JL: Statistical Methods for Rates and Proportions. 2nd edition. John Wiley & Sons, Inc; New York: 1981
29.	Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar
30.	Cox DR: Regression models and life tables. JR Stat Soc B. 34:187–220. 1972.
31.	Armitage P, Berry G and Matthews JNS: Statistical methods in Medical Research. 4th edition. Blackwell Publishing; Oxford: 2000
32.	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Mohler JM: A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab. 22:357–372. 2008. View Article : Google Scholar : PubMed/NCBI
34.	Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, Hentze MW and Ronai Z: ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol. 3:325–330. 2001. View Article : Google Scholar : PubMed/NCBI
35.	Hong SK, Jeong JH, Chan AM and Park JI: AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res. 319:1732–1743. 2013. View Article : Google Scholar : PubMed/NCBI
36.	Fiorentino M, Capizzi E and Loda M: Blood and tissue biomarkers in prostate cancer: State of the art. Urol Clin North Am. 37:131–141. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Sadi M and Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer. 71:2574–2580. 1993. View Article : Google Scholar
38.	Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C and Loda M: Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol. 10:8398–8445. 1997.
39.	Mikula M and Ostrowski J: HNRNP K (heterogeneous nuclear ribonucleoprotein K). Atlas Genet Cytogenet Oncol Haematol. 14:127–129. 2010.
40.	Shi L, Ko S, Kim S, Echchgadda I, Oh TS, Song CS and Chatterjee B: Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein-regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J Biol Chem. 283:36474–36485. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Inoue A, Sawata SY, Taira K and Wadhwa R: Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci USA. 104:8983–8988. 2007. View Article : Google Scholar
42.	Benelli R, Monteghirfo S, Balbi C, Barboro P and Ferrari N: Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer. 124:2989–2996. 2009. View Article : Google Scholar : PubMed/NCBI
43.	Paliouras M, Zaman N, Lumbroso R, Kapogeorgakis L, Beitel LK, Wang E and Trifiro M: Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes. Integr Biol. 3:1020–1032. 2011. View Article : Google Scholar : PubMed/NCBI
44.	Chmelar R, Buchanan G, Need EF, Tilley W and Greenberg NM: Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer. 120:719–733. 2007. View Article : Google Scholar : PubMed/NCBI
45.	Barboro P, Borzì L, Repaci E, Ferrari N and Balbi C: Androgen Receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells. PLoS One. 8:e792122013. View Article : Google Scholar
46.	McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
47.	Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, Balbi C and Ferrari N: Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. Int J Cancer. 131:582–590. 2012.PubMed/NCBI
48.	Gao R, Yu Y, Inoue A, Widodo N, Kaul SC and Wadhwa R: Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem. 288:15046–15056. 2013. View Article : Google Scholar : PubMed/NCBI